Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2012

Open Access 01-12-2012 | Primary research

Osteopontin’s colocalization with the adhesion molecule CEACAM5 in cytoplasm of carcinoma of tongue and its correlation with the invasion of that diease

Authors: Fan Zhang, Xu Jin Liu, Xun Qu, Zhen Sheng Hu, Yong Mei Yang, Ling Ma, Pei Liu, Ping Shi, Feng Cai Wei

Published in: Cancer Cell International | Issue 1/2012

Login to get access

Abstract

The purpose of this study was to investigate the expression of carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) and correlate it with OPN expression and function in squamous carcinoma of tongue.
Paraffin were sections of 80 samples with squamous carcinoma of tongue and 40 samples with normal tissue of tongue for benign lesion having undergone surgery. Immunohistochemistry (IHC) was used to study the distribution of CEACAM5 and OPN, and double–labeling immunohistochemistry was used to observe the relationship between CEACAM5 and OPN expression.
CEACAM5 and OPN are found in normal tissue of tongue, but with different expression pattern. CEACAM5 expression mainly with membranous staining is restricted on the superficial epithelium. However, OPN expression with mainly cytoplasmic staining is restricted on the deep epithelium. No colocalization of CEACAM5 and OPN have been observed in normal tissue of tongue. In squamous carcinoma of tongue, CEACAM5 expression with cytoplasmic staining is different from normal tongue tissue with membranous staining, and the transformation of CEACAM5 distribution from membrane to cytoplasm is an important incident for the invasion and differentiation of tumor. CEACAM5 and OPN are colocalized in cytoplasm, and a significant correlation was observed between the positive colocalization and the negative colocalization in the depth of invasion and the differentiation of the tumor.
Appendix
Available only for authorised users
Literature
1.
Steller H: Mechanisms and genes of cellular suicide. Science. 1995, 267: 1445-1449. 10.1126/science.7878463.CrossRefPubMed
2.
Thompson CB: Apoptosis in the pathogenesis and treatment of disease. Science. 1995, 267: 1456-1462. 10.1126/science.7878464.CrossRefPubMed
3.
Liaw L, Almeida M, Hart CE, Schwarz SM, Giachelli CM: The adhesive and migratory effects of osteopontin are mediated via distinct cell surface integrins: role of alpha v beta 3 in smoothmuscle cellmigration to osteopontin in vitro. J Clin Invest. 1995, 95: 713-724. 10.1172/JCI117718.PubMedCentralCrossRefPubMed
4.
Daiter E, Omigbodun A, Wang S, Walinsky D, Strauss JF, Hoyer JR, Coutifaris C: Cell differentiation and endogenous cyclic adenosine 3,5,-monophosphate regulate osteopontin expression in human trophoblasts. Endocrinology. 1996, 137: 1785-1790. 10.1210/en.137.5.1785.PubMed
5.
Yue TL, McKenna PJ, Ohlstein EH, Farach-Carson MC, Butler WT, Johanson K, McDevitt P, Feuerstein GZ, Stadel JM: Osteopontin-stimulated vascular smooth muscle cell migration is mediated by beta 3 integrin. Exp Cell Res. 1994, 214: 459-464. 10.1006/excr.1994.1282.CrossRefPubMed
6.
Johnson GA, Burghardt RC, Bazer FW, Spencer TE: Osteopontin: roles in implantation and placentation. Biol Reprod. 2003, 69: 1458-1471. 10.1095/biolreprod.103.020651.CrossRefPubMed
7.
Brown LF, Berse B, Van de Water L, Papadopoulos-Sergiou A, Perruzzi CA, Manseau EJ, Dvorak HF, Senger DR: Expression and distribution of osteopontin in human tissues. Biol Cell. 1992, 3: 1169-1180.
8.
Rittling SR, Novick KE: Osteopontin expression in mammary gland development and tumorigenesis. Cell Growth Differ. 1997, 8: 1061-1069.PubMed
9.
Beauchemin N, Draber P, Dveksler G, Gold P, Gray-Owen S, Grunert F, Hammerstrom S, Holmes KV, Karlsson A, Kuroki M, Lin SH, Lucka L, Najjar SM, Neumaier M, Obrink B, Shively JE, Skubitz KM, Stanners CP, Thomas P, Thompason JA, Virji M, von Kleist S, Wagener C, Watt S, Zimmermann W: Redefined nomenclature for members of the carcinoembryonic antigen family. Exp Cell Res. 1999, 252: 243-249.CrossRefPubMed
10.
11.
Goldenberg DM, Sharkey RM, Primus FJ: Carcinoembryonic antigen in histopathology: immunoperoxidase staining of conventional tissue sections. J Natl Cancer Inst. 1976, 57: 11-22.PubMed
12.
Shively JE, Beatty JD: CEA-related antigens: molecular biology and clinical significance. Crit Rev Oncol Hematol. 1985, 2: 355-399. 10.1016/S1040-8428(85)80008-1.CrossRefPubMed
13.
Thompson JA, Grunert F, Zimmermann W: Carcinoembryonic antigen gene family: molecular biology and clinical perspectives. J Clin Lab Anal. 1991, 5: 344-366. 10.1002/jcla.1860050510.CrossRefPubMed
14.
Gold P, Goldenberg NA: The carcinoembryonic antigen (CEA): past present, and future. McGill J Med. 1997, 3: 46-66.
15.
Hammarstrom S: The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Semin Cancer Biol. 1999, 9: 67-81. 10.1006/scbi.1998.0119.CrossRefPubMed
16.
Briese J, Oberndorfer M, Patschenik C, Schulte HM, Makriqiannakis A, Loning T, Bamberger AM: Osteopontin Is Colocalized with the Adhesion Molecule CEACAM1 in the Extravillous Trophoblast of the Human Placenta and Enhances Invasion of CEACAM1-Expressing Placental Cells. J Clin Endocrinol Metab. 2005, 90: 5407-5413. 10.1210/jc.2004-2434.CrossRefPubMed
17.
Obrink B: CEAadhesion molecules: multifunctional proteins with signal-regulatory properties. Curr Opin Cell Bior. 1997, 9: 616-626. 10.1016/S0955-0674(97)80114-7.CrossRef
18.
Beauchemin N, Kunath T, Tobitaille J: Association of biliary glycoprotein with protein tyrosine phosphatase SHP-1 in malignant colon epithelial cells. Oncogene. 1997, 14: 783-790. 10.1038/sj.onc.1200888.CrossRefPubMed
19.
Lutz Riethdorf L, Lisboa BW, Henkel U, Naumann M, Waqener C, Loning T: Differential expression of CD66a (BGP), a cell adhesion molecule of the carcinoembryonic antigen family, in benign, premalignant, and malignant lesions of the human mammary gland. J Histochem Cytochem. 1997, 45: 957-964. 10.1177/002215549704500705.CrossRef
20.
Giachelli CM, Steitz S: Osteopontin: a versatile regulator of inflammation and biomineralization. Matrix Biol. 2000, 19: 615-622. 10.1016/S0945-053X(00)00108-6.CrossRefPubMed
21.
Senger DR, Ledbetter SR, Claffey KP, PapadopoulosSergiou A, Perruzzi CA, Detmar M: Stimulation of endothelial cell migration by vascular permeability factor/vascular endothelial growth factor through cooperative mechanisms involving the αv ß3 integrin, osteopontin, and thrombin. Am J Pathol. 1996, 149: 293-305.PubMedCentralPubMed
22.
Denhardt DT, Guo X: Osteopontin: a protein with diverse functions. FASEB J. 1993, 7: 1475-1482.PubMed
23.
Shijubo N, Uede T, Kon S, Nagata M, Abe S: Vascular endothelial growth factor and osteopontin in tumor biology. Crit Rev Oncog. 2000, 11: 135-146.PubMed
24.
Morimoto J, Inobe M, Kimura C, Kon S, Diao H, Aoki M, Miyazaki T, Denhardt DT, Rittling S, Uede T: Osteopontin affects the persistence of β-glucan-induced hepatic granuloma formation and tissue injury through two distinct mechanisms. Int Immunol. 2004, 16: 477-488. 10.1093/intimm/dxh044.CrossRefPubMed
25.
Coppola D, Szabo M, Boulware D, Muraca P, Alsarraj M, Chambers AF, Yeatman TJ: Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res. 2004, 10: 184-190. 10.1158/1078-0432.CCR-1405-2.CrossRefPubMed
26.
Chien CY, Su CY, Fang FM, Huang HY, Chen CM, Chen CH, Huang CC: Clinical significance of osteopontin expression in T1 and T2 tongue cancers. Head Neck. 2008, 30: 776-781. 10.1002/hed.20783.CrossRefPubMed
27.
Chiu YW, Tu HF, Wang IK, Wu CH, Chang KW, Liu TY, Kao SY: The implication of osteopontin (OPN) expression and genetic polymorphisms of OPN promoter in oral carcinogenesis. Oral Oncol. 2010, 46: 302-306. 10.1016/j.oraloncology.2010.01.018. Epub 2010 Mar 9CrossRefPubMed
Metadata
Title
Osteopontin’s colocalization with the adhesion molecule CEACAM5 in cytoplasm of carcinoma of tongue and its correlation with the invasion of that diease
Authors
Fan Zhang
Xu Jin Liu
Xun Qu
Zhen Sheng Hu
Yong Mei Yang
Ling Ma
Pei Liu
Ping Shi
Feng Cai Wei
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2012
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/1475-2867-12-33

Other articles of this Issue 1/2012

Cancer Cell International 1/2012 Go to the issue

Review

Pathobiology of cancer metastasis: a short account

Review

Algae extracts and methyl jasmonate anti-cancer activities in prostate cancer: choreographers of ‘the dance macabre’

Review

Rituximab and new regimens for indolent lymphoma: a brief update from 2012 ASCO Annual Meeting

Primary research

ZIP8 expression in human proximal tubule cells, human urothelial cells transformed by Cd+2 and As+3 and in specimens of normal human urothelium and urothelial cancer

Primary research

Lycorine induces cell-cycle arrest in the G0/G1 phase in K562 cells via HDAC inhibition

Primary research

Unique functions of CHK1 and WEE1 underlie synergistic anti-tumor activity upon pharmacologic inhibition
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits